ATRYS HEALTH S.A. EO-01
Atrys Health, S.A., together with its subsidiaries, provides diagnostic services and medical treatments in Spain, Portugal, and Latin America. It operates through Diagnosis, Oncology, and Preventive Medicine segments. The company offers integrated diagnostics services comprising structural and molecular pathology, genetics, and nuclear medicine diagnosis; online medical imaging in the fields of r… Read more
Market Cap & Net Worth: ATRYS HEALTH S.A. EO-01 (A2T)
ATRYS HEALTH S.A. EO-01 (F:A2T) has a market capitalization of $211.97 Million (€206.51 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #17583 globally and #1834 in its home market, demonstrating a 5.02% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ATRYS HEALTH S.A. EO-01's stock price €2.72 by its total outstanding shares 75921546 (75.92 Million).
ATRYS HEALTH S.A. EO-01 Market Cap History: 2021 to 2026
ATRYS HEALTH S.A. EO-01's market capitalization history from 2021 to 2026. Data shows change from $738.79 Million to $211.97 Million (-22.04% CAGR).
ATRYS HEALTH S.A. EO-01 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ATRYS HEALTH S.A. EO-01's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of A2T by Market Capitalization
Companies near ATRYS HEALTH S.A. EO-01 in the global market cap rankings as of March 19, 2026.
Key companies related to ATRYS HEALTH S.A. EO-01 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
ATRYS HEALTH S.A. EO-01 Historical Marketcap From 2021 to 2026
Between 2021 and today, ATRYS HEALTH S.A. EO-01's market cap moved from $738.79 Million to $ 211.97 Million, with a yearly change of -22.04%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €211.97 Million | +1.12% |
| 2025 | €209.64 Million | -17.74% |
| 2024 | €254.84 Million | -10.90% |
| 2023 | €286.01 Million | -40.61% |
| 2022 | €481.62 Million | -34.81% |
| 2021 | €738.79 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of ATRYS HEALTH S.A. EO-01 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $211.97 Million USD |
| MoneyControl | $211.97 Million USD |
| MarketWatch | $211.97 Million USD |
| marketcap.company | $211.97 Million USD |
| Reuters | $211.97 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.